| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
| US8912210 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Dec, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833448 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) | |
| US11717515 | ABBVIE | Treatment of migraine |
Dec, 2041
(17 years from now) | |
Ubrelvy is owned by Abbvie.
Ubrelvy contains Ubrogepant.
Ubrelvy has a total of 6 drug patents out of which 0 drug patents have expired.
Ubrelvy was authorised for market use on 23 December, 2019.
Ubrelvy is available in tablet;oral dosage forms.
Ubrelvy can be used as acute treatment of migraine with or without aura in a patient with severe hepatic impairment, acute treatment of migraine with or without aura in adults, acute treatment of migraine with headache, with or without aura in adults.
Drug patent challenges can be filed against Ubrelvy from 24 December, 2023.
The generics of Ubrelvy are possible to be released after 22 December, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with or without aura in a patient with severe hepatic impairment; Acute treatment of migraine with headache, wit...
Dosage: TABLET;ORAL
UBRELVY family patents
